Get Free Delivery With No Minimum Order
-1744229570.gif "Almujtama Pharmacy logo"){kind=small}
Health Care & Wellness > Diabetes Care
Health Care & Wellness > Diabetes Care
Skin And Body Care > Moisturizers
Skin And Body Care > Moisturizers
Skin And Body Care > Moisturizers
WEGOVY 0.5 MG INJECTION
- Sku : I-033614
Key features
WEGOVY 0.5 mg injection is a solution for injection in a pre-filled pen containing semaglutide 0.5 mg. It is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that enhances glucose‑dependent insulin secretion, reduces inappropriate glucagon release, slows gastric emptying and suppresses appetite via central pathways. WEGOVY is indicated for chronic weight management as an adjunct to a reduced‑calorie diet and increased physical activity in adults with obesity, adults with overweight plus at least one weight‑related comorbidity, and pediatric patients aged 12 years and older with obesity; it is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Available by prescription as a 4‑dose pre-filled pen for subcutaneous administration.- Active Ingredient: SEMAGLUTIDE 0.5mg
- Strength: 0.5mg
- Dosage Form: Solution for injection in pre-filled pen
- Pack Size: 4 dose
- Route: Subcutaneous use
- Prescription Status: Prescription
- Therapeutic Class: Antidiabetic
- Pharmacological Group: GLP-1 Receptor Agonists
- Drug Class: GLP-1 Receptor Agonist (Glucagon-Like Peptide-1 Receptor Agonist), long-acting subcutaneous formulation
- Manufacturer: NOVO NORDISK
- Country of Origin: Denmark
- SFDA Registration No.: 2101256698
- Shelf Life: 36 months
- Storage: store in a refrigerator (2°c - 8°c)
- Diabetes Type: Type 2
Health Care & Wellness > Diabetes Care
Health Care & Wellness > Diabetes Care
Skin And Body Care > Moisturizers
Skin And Body Care > Moisturizers
Skin And Body Care > Moisturizers
Indications
Approved Uses
Chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity: (1) adults with obesity, or overweight with at least one weight-related comorbidity; and (2) pediatric patients aged 12 years and older with obesity. Also approved to reduce the risk of major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
Dosage & Administration
Dosing by Condition
For Wegovy indications (weight management and cardiovascular risk reduction): 0.25 mg SC once weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg for 4 weeks, then 1.7 mg for 4 weeks, then maintenance 2.4 mg once weekly (or 1.7 mg if 2.4 mg not tolerated).
Maintenance Dose
1.7 mg or 2.4 mg subcutaneously once weekly.
Maximum Dose
2.4 mg subcutaneously once weekly.
Pharmacology
Mechanism of Action
GLP-1 receptor agonist that increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying, and reduces appetite/energy intake via central pathways.
Duration of Effect
Approximately 7 days, supporting once-weekly dosing.
Half-Life
Approximately 1 week (~7 days; about 165-184 hours).
Bioavailability
Approximately 89% (subcutaneous absolute bioavailability).
Metabolism
Metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty-acid side chain; not meaningfully metabolized by CYP450 enzymes.
Protein Binding
>99% bound to plasma proteins (primarily albumin).
Product Information
Available Dosage Forms
Solution for injection in pre-filled pen (subcutaneous use)
Generic Availability
No
OTC Alternatives
No OTC alternative
Diabetes Type
Type 2
Legal Disclaimer - Al Mujtama Pharmacy
The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Al Mujtama Pharmacy assumes no legal or medical liability for:
- Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
- Any discrepancy between the information provided and the product's package insert or SFDA guidelines
- Any misuse of medication resulting from personal interpretation of the content displayed
Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.
By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.
Your health is a trust - always consult your doctor first.
